COVID-19 and the nicotinic cholinergic system
Konstantinos Farsalinos, Athina Angelopoulou, Nikolaos Alexandris, Konstantinos Poulas
Abstract
<b>The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options.</b>https://bit.ly/2zfUZ1S
Topics & Concepts
MedicineCholinergicNicotinic agonistCoronavirus disease 2019 (COVID-19)Cholinergic system2019-20 coronavirus outbreakInternal medicineVirologyReceptorDiseaseOutbreakInfectious disease (medical specialty)Nicotinic Acetylcholine Receptors StudyVagus Nerve Stimulation ResearchOlfactory and Sensory Function Studies